CC
FOLD

CQS Cayman’s Amicus Therapeutics FOLD Stock Holding History

CQS Cayman’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,623,000
Closed -$12M – 124
2016
Q3 		$12M Buy
1,623,000
+233,000
+17% +$1.57M 1.01% 31
2016
Q2 		$7.59M Buy
+1,390,000
New +$9.72M 0.67% 41

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

CQS Cayman's FOLD Position: Q4 2016 in Review

CQS Cayman sold out of Amicus Therapeutics (FOLD) in Q4 2016, closing a stake of 1,623,000 shares — an estimated $12M sold.

CQS Cayman first reported a position in FOLD in Q2 2016 and held it in 2 quarters. The position peaked at $12M in Q3 2016. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

  • CQS Cayman reported no remaining Amicus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • CQS Cayman sold 1,623,000 Amicus Therapeutics shares in Q4 2016, an estimated $12M.
  • CQS Cayman first reported a position in Amicus Therapeutics in Q2 2016 and held it in 2 quarters.
  • CQS Cayman's Amicus Therapeutics position peaked at $12M in Q3 2016.
  • 135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on CQS Cayman's 13F filing for Q4 2016, filed 14 Feb 2017.